Phase 2 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

About this Trial

Phase 2 multicenter study to be conducted in up to 50 qualified participating sites in the United States to assess the efficacy and safety of Reltecimod vs placebo in patients with abdominal sepsis-associated Stage 2/3 AKI.

• Status: Enrolling now
• Location: Miami Valley Hospital
• Study type: Interventional
• Ages eligible for study: 18 and older
• Genders eligible for study: Both
• Principal Investigator: Peter Ekeh, MD
• For more information about this study, visit ClinicalTrials.gov: NCT03403751

Contact Us

If you would like information about participating in this study, contact:

Linda Clark
(937) 208-2913
lclark@premierhealth.com